Post-COVID-19 Consumer Preferences Provide Roadmap For Strategy Across Health Care Sectors
Post-COVID, a consumer’s home as point of care has led to greater acceptance for health gadgets while shifting preferences away from injectables, shows a new study, which has pointers for pharma strategy. With anxiety over the pandemic continuing, mental telehealth solutions are ripe for the picking.
You may also be interested in...
The merger between virtual care companies Teladoc and Livongo will offer individuals a wide range of tech-enabled care during a time when telehealth continues to grow.
Will FDA-cleared prescription digital therapeutics be able to follow wellness, chronic disease and sleep disorder apps onto the formularies of major payers? For digital therapeutics companies investing in randomized controlled clinical trials, GMP manufacturing and FDA submissions for products, the current absence of public health insurance coverage is frustrating.
Industry is limiting face-to-face interactions between sales reps and physicians, and some patients are sitting out visits, amid the COVID-19 outbreak. That poses big business challenges for pharma.